View Expired Tender

Get immediate access to tenders like the one below by subscribing now to Tenders Direct. We will set up your personalised profile and send you tender alerts direct to your mailbox as soon as they are published. You will also benefit from having access to historical tenders.

Notice Summary

UK-Southampton: 19/29 Frequency of Blood Tests for Inflammatory Conditions
GB003ZM293891
National Institute for Health Research (NIHR)
19 April 2019
25 September 2019
Contract Notice - Other
No

Notice Abstract

19/29 Frequency of blood tests for inflammatory conditions Rationale: Common inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease and the spondyloarthritides, are commonly treated with immunosuppressive drugs, such as disease-modifying anti-rheumatic drugs (DMARDs). Many of these disease-modifying drugs carry a risk of adverse events (e.g. hepatotoxicity) and thus require careful monitoring with the use of blood tests such as full blood count, liver function tests and urea and electrolyte tests. For this patient group there is uncertainty as to the optimum frequency of monitoring. Evidence suggests that for a large majority of people using these drugs, adverse events are very unlikely and the monitoring regimen itself may represent a greater burden. Testing too often is costly and places significant burden on the patient and the healthcare system, but not testing often enough could increase the risk of adverse events occurring. In recent years, this routine testing has moved into primary care. Drug manufacturers and medical guidelines provide advice on the frequency of testing (NICE guidance recommends regular blood monitoring, generally every 3 months) but these may not be strictly followed. Therefore, the HTA programme wishes to commission research to determine the optimum strategy for the frequency of routine blood testing for patients with inflammatory conditions taking long-term immunosuppressive medication.

Notice Details

CONTRACT NOTICE – NATIONAL

SERVICES

1 Authority Details

1.1

Authority Name and Address


National Institute for Health Research (NIHR)

N/A

Southampton


UK

N/A

N/A


N/A

1.2

Address from which documentation may be obtained

As in 1.1

1.3

Completed documents must be returned to:

As in 1.1

2 Contract Details

2.1

Title

19/29 Frequency of Blood Tests for Inflammatory Conditions

2.2

Description of the goods or services required

19/29 Frequency of blood tests for inflammatory conditions

Rationale:

Common inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease and the spondyloarthritides, are commonly treated with immunosuppressive drugs, such as disease-modifying anti-rheumatic drugs (DMARDs).

Many of these disease-modifying drugs carry a risk of adverse events (e.g. hepatotoxicity) and thus require careful monitoring with the use of blood tests such as full blood count, liver function tests and urea and electrolyte tests. For this patient group there is uncertainty as to the optimum frequency of monitoring. Evidence suggests that for a large majority of people using these drugs, adverse events are very unlikely and the monitoring regimen itself may represent a greater burden. Testing too often is costly and places significant burden on the patient and the healthcare system, but not testing often enough could increase the risk of adverse events occurring. In recent years, this routine testing has moved into primary care. Drug manufacturers and medical guidelines provide advice on the frequency of testing (NICE guidance recommends regular blood monitoring, generally every 3 months) but these may not be strictly followed.

Therefore, the HTA programme wishes to commission research to determine the optimum strategy for the frequency of routine blood testing for patients with inflammatory conditions taking long-term immunosuppressive medication.

2.3

Notice Coding and Classification

2.4

Total quantity or scope of tender

3 Conditions for Participation

3.1

Minimum standards and qualification required

4 Administrative Information

4.1

Type of Procedure

The procedure type is unknown.

4.2

Reference number attributed to the notice by the contracting authority

19/29

4.3

Time Limits

   25-09-2019  Time 13:00

4.5

Language or languages in which tenders or requests to participate can be drawn up

EN 

4.6

Tender Submission Postbox

5 Other Information

5.1

Additional Information

Please visit the following portal to view this notice:

https://www.nihr.ac.uk/funding-and-support/funding-opportunities/1929-frequency-of-blood-tests-for-inflammatory-conditions/10557

The deadline for applications is 1pm, 25 September 2019.

(MT Ref:293891)

5.2

Additional Documentation

5.3

Publication date of this notice

 19-04-2019